Anika Appoints David Colleran as General Counsel
March 04 2020 - 8:30AM
Business Wire
Seasoned executive brings extensive experience
leading corporate legal and governance teams
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
joint preservation and regenerative therapies company with products
leveraging its proprietary hyaluronic acid (HA) technology
platform, today announced the appointment of David Colleran to the
newly created position of Executive Vice President, General Counsel
and Corporate Secretary. In this new role, Mr. Colleran will lead
the Company’s global legal organization, including corporate
governance and compliance.
“We are delighted to welcome another strong leader to Anika,”
said Cheryl Blanchard, Ph.D., interim Chief Executive Officer of
Anika Therapeutics. “David has a proven record leading corporate
legal and governance activities for global medical device and
biotech companies, and his extensive experience in mergers and
acquisitions, strategic alliances, intellectual property, and
regulatory affairs will be invaluable to Anika as we continue to
execute on our five-year strategic plan.”
“I am thrilled to join Anika’s executive team at this very
exciting stage in the Company’s evolution,” said David Colleran,
Executive Vice President, General Counsel and Corporate Secretary
of Anika Therapeutics. “Anika is well-positioned to bring
innovative solutions to patients around the world, and I look
forward to contributing to the Company’s continued growth.”
Prior to joining Anika, Mr. Colleran served as Senior Vice
President, General Counsel, Corporate Secretary and Chief
Compliance Officer at Insulet Corporation, a publicly traded,
global medical device and drug delivery company. Prior to Insulet,
he held the role of Vice President and General Counsel at Covidien,
a global manufacturer of medical devices and supplies acquired by
Medtronic, and Corporate Counsel at Ocean Spray Cranberries. Mr.
Colleran began his career as a corporate attorney at Choate, Hall
& Stewart. He received a Bachelor of Arts in Political Science
from Boston College and a Juris Doctor from Boston College Law
School. Click here to view his full bio.
About Anika Therapeutics
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
joint preservation and regenerative therapies company based in
Bedford, Massachusetts. Anika is committed to delivering therapies
to improve the lives of patients across a continuum of care from
osteoarthritis pain management to joint preservation and
restoration. The Company has over two decades of global expertise
commercializing more than 20 products based on its proprietary
hyaluronic acid (HA) technology platform. For more information
about Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200304005050/en/
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer
investorrelations@anikatherapeutics.com
For Media Inquiries: W2O Group Jeremy Berrington, 312-241-1995
jberrington@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024